ten Bosch John Roderick sold $298K of BLLN

ten Bosch John Roderick (SVP of Laboratory Operations) sold 2,834 shares of BillionToOne, Inc. (BLLN) at $105.15 ($0.30M total) across 2 trades on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Oct 7, 2026, 11:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 11:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The disclosed sale adds a modest bearish nuance to BLLN's short‑term outlook, though the overall impact is limited given the company's size and the pre‑arranged nature of the trade.

02

Market read

The filing is a primary source of new information for BLLN shareholders and may prompt short‑term price adjustments.

03

What to watch

Potential upcoming milestones or financing that may offset the sell pressure.

Relevance 3/10Novelty 3/10Timing: after‑hours filing on 2026‑10‑07

Background

Form 4 filings provide the first public record of insider transactions, offering transparency into insider sentiment.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

SEC Form 4 disclosed that SVP John Roderick sold 2,834 shares of BillionToOne for $298K via a 10b5‑1 plan.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

A senior officer sold a sizable block under a pre‑arranged plan; such sales often signal limited confidence and can prompt short‑term dips.

Market effects

Minimal impact on the biotech/clinical‑trial sector; the sale is company‑specific.

No broader regional effect.

Limited to investors tracking BLLN.

Counterpoint

The sale could be routine liquidity management, not a negative signal.

Key entities

  • BillionToOne, Inc.

    US‑listed biotech firm (ticker BLLN) subject of the insider sale.

  • John Roderick

    SVP of Laboratory Operations at BillionToOne, insider seller.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.